# **United States Securities and Exchange Commission** Washington, D.C. 20549

# **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

iled by the Registrant 🗵			
Filed by a Party other than the Registrant □			
Check the appropriate box:			
□ Preliminary Proxy Statement			
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))			
□ Definitive Proxy Statement			
☑ Definitive Additional Materials			
□ Soliciting Material under §240.14a-12			
DERMATA THERAPEUTICS, INC.			
(Name of Registrant as Specified in its Charter)			
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)			
Payment of Filing Fee (Check all boxes that apply):			
☑ No fee required			
☐ Fee paid previously with preliminary materials			
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11			



**DERMATA THERAPEUTICS, INC.** 

2025 Annual Meeting Vote by July 14, 2025 11:59 PM ET

DERMATA THERAPEUTICS, INC. 3525 DEL MAR HEIGHTS ROAD, #322 SAN DIEGO. CA 92130



V75686-P33014

### You invested in DERMATA THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on July 15, 2025.

#### Get informed before you vote

View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to July 1, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

#### **Smartphone users**

Point your camera here and vote without entering a control number





#### Vote Virtually at the Meeting\*

July 15, 2025 9:00 am Pacific Time

Virtually at: www.virtualshareholdermeeting.com/DRMA2025

<sup>\*</sup>Please check the meeting materials for any special requirements for meeting attendance.

## THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Vot	Voting Items		
1.	Election of Directors		
	Nominees:		
	To be elected for terms expiring in 2028	<b>○</b> For	
	<ul><li>01) Mary Fisher</li><li>02) Andrew Sandler</li></ul>		
2.	To ratify the appointment of Moss Adams LLP, or any successor entity thereto, as the Company's independent registered public accounting firm for the year ending December 31, 2025.	<b>⊘</b> For	
3.	To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying certain warrants issued pursuant to that certain Securities Purchase Agreement, dated as of January 21, 2025, in an amount equal to or in excess of 20% of the Company's Common Stock outstanding immediately prior to the issuance of such warrants.	<b>⊘</b> For	
4.	To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock underlying certain warrants issued by the Company pursuant to that certain Inducement Letter, dated as of March 27, 2025, in an amount equal to or in excess of 20% of the Company's Common Stock outstanding immediately prior to the issuance of such warrants.	<b>⊘</b> For	
5.	To approve an amendment to the Certificate of Incorporation, at the discretion of the Board, to effect a reverse stock split of the issued and outstanding shares of the Company's Common Stock at a specific ratio, ranging from one-for-two (1:2) to one-for-thirty (1:30), at any time prior to the one-year anniversary date of the 2025 Annual Meeting, with the exact ratio to be determined by the Board.	For	
6.	To approve the adjournment of the Annual Meeting in the event that the number of shares of common stock present or represented by proxy at the Annual Meeting and voting "FOR" the adoption of Proposal 3, Proposal 4, and/or Proposal 5 are insufficient.	For	
7.	To consider any other matters that properly come before the 2025 Annual Meeting.		

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".